OBJECTIVES: Pegylated liposomal doxorubicin (PLD) has improved therapy options significantly, as it causes less myelosuppression, nausea, vomiting, and alopecia than conventional doxorubicin, while maintaining efficacy. The goal of this survey was to determine whether the use of PLD in a community-based patient group is comparable regarding chemotherapeutic doses and side effects to preselected study patients. METHODS: 100 questionnaires were randomly sent to Swiss oncologists in private practices, general hospitals and university hospitals. RESULTS: The patient cohort was heterogeneous with respect to prior treatments. PLD was an active agent in metastatic breast cancer and was well tolerated by the majority of patients. The most common non-hematological side effects were hand-foot syndrome (HFS) and mucositis while only patients receiving a dose of 50 mg/m(2) (recommended dose) experienced grade 4 HFS. The reported mean dose of PLD was 38.5 mg/m(2). CONCLUSIONS: This community-based observational study supports previous reports indicating that PLD at a median dose of < or =40 mg/m(2) every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer. (c) 2007 S. Karger AG, Basel
OBJECTIVES: Pegylated liposomal doxorubicin (PLD) has improved therapy options significantly, as it causes less myelosuppression, nausea, vomiting, and alopecia than conventional doxorubicin, while maintaining efficacy. The goal of this survey was to determine whether the use of PLD in a community-based patient group is comparable regarding chemotherapeutic doses and side effects to preselected study patients. METHODS: 100 questionnaires were randomly sent to Swiss oncologists in private practices, general hospitals and university hospitals. RESULTS: The patient cohort was heterogeneous with respect to prior treatments. PLD was an active agent in metastatic breast cancer and was well tolerated by the majority of patients. The most common non-hematological side effects were hand-foot syndrome (HFS) and mucositis while only patients receiving a dose of 50 mg/m(2) (recommended dose) experienced grade 4 HFS. The reported mean dose of PLD was 38.5 mg/m(2). CONCLUSIONS: This community-based observational study supports previous reports indicating that PLD at a median dose of < or =40 mg/m(2) every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer. (c) 2007 S. Karger AG, Basel
Authors: Ruth M Urbantat; Valentin Popper; Elisabeth Menschel; Michael Pfeilstöcker; Ernst Forjan; Alexander Nader; Catherine R Sieghart; Felix Keil; Elisabeth Koller Journal: Clin Case Rep Date: 2021-02-12
Authors: Jens Huober; Werner Fett; Arnd Nusch; Michael Neise; Marcus Schmidt; Arthur Wischnik; Steffen Gerhardt; Thomas Goehler; Hans-Joachim Lück; Andreas Rost Journal: BMC Cancer Date: 2010-01-05 Impact factor: 4.430